Psychedelics Company's $60M Series A For Startup To Develop Treatment For Mental Health Disorders
Biotech company focused on creating next-gen serotonergic neuroplastogen psychedelic compounds to treat severe neuropsychiatric and neurological conditions Lusaris Therapeutics launched with a $60 million Series A financing.
